RJA
VIVO

Raymond James & Associates’s Meridian Bioscience Inc VIVO Stock Holding History

Raymond James & Associates’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,133
Closed -$403K – 4154
2022
Q4 		$403K Sell
12,133
-6,875
-36% -$221K ﹤0.01% 3027
2022
Q3 		$599K Buy
19,008
+6,414
+51% +$208K ﹤0.01% 2740
2022
Q2 		$383K Buy
12,594
+1,097
+10% +$29.7K ﹤0.01% 3070
2022
Q1 		$298K Sell
11,497
-471
-4% -$11.2K ﹤0.01% 3419
2021
Q4 		$244K Sell
11,968
-11,198
-48% -$215K ﹤0.01% 3574
2021
Q3 		$446K Sell
23,166
-54,163
-70% -$1.08M ﹤0.01% 3148
2021
Q2 		$1.72M Sell
77,329
-12,059
-13% -$256K ﹤0.01% 2208
2021
Q1 		$2.35M Sell
89,388
-6,465
-7% -$154K ﹤0.01% 1910
2020
Q4 		$1.79M Buy
95,853
+5,367
+6% +$100K ﹤0.01% 1955
2020
Q3 		$1.54M Sell
90,486
-19,106
-17% -$371K ﹤0.01% 1919
2020
Q2 		$2.55M Buy
109,592
+12,736
+13% +$185K ﹤0.01% 1577
2020
Q1 		$814K Buy
+96,856
New +$815K ﹤0.01% 2120
2015
Q4 		– Sell
-14,167
Closed -$242K – 2414
2015
Q3 		$242K Buy
+14,167
New +$259K ﹤0.01% 2197
2013
Q3 		– Sell
-30,096
Closed -$647K – 2002
2013
Q2 		$647K Buy
+30,096
New +$649K 0.01% 1379

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James & Associates's VIVO Position: Q1 2023 in Review

Raymond James & Associates sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 12,133 shares — an estimated $403K sold.

Raymond James & Associates first reported a position in VIVO in Q2 2013 and held it in 14 quarters. The position peaked at $2.55M in Q2 2020. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Raymond James & Associates reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 12,133 Meridian Bioscience Inc shares in Q1 2023, an estimated $403K.
  • Raymond James & Associates first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 14 quarters.
  • Raymond James & Associates's Meridian Bioscience Inc position peaked at $2.55M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.